Drug
Atogepant clinical trials
Also written Qulipta and AGN-241689.
- studies test it
- 22
- open now
- 6
- in phase 3
- 16
- first study started
- 2016
Keep track of what changes. Save the atogepant studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
21 studies that test it; most in 2021 (4); 1 more planned to start later
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2018 | 2 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 4 |
| 2022 | 2 |
| 2023 | 4 |
| 2024 | 1 |
| 2025 | 3 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 1
- Phase 3
- 16
- Phase 4
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 19 · Other 3
AbbVie (12) · Allergan (7) · Konrad Peter Weber (1) · Stanford University (1) · Mayo Clinic (1)
Often tested with
Tested in the same studies.
Ubrogepant (2) · Galcanezumab (1) · Erenumab (1) · Eptinezumab (1) · Propranolol (1) · Topiramate (1)
Studies
Open first, then newest update. How each study uses atogepant is read from its arms, and is right about nine times in ten.
Testing it · 22
- Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison StudyRecruitingPhase 4Mayo ClinicNCT06972056Written as Atogepant 60 mg
- A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 YearsRecruitingPhase 3AbbVieNCT06810505Written as Atogepant
- A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic MigraineRecruitingPhase 3AbbVieNCT05711394Written as Atogepant
- Effect of Atogepant on the Vestibulo-Ocular Reflex in Healthy Adults and Adults With MigraineNot yet recruitingPhase 4Konrad Peter WeberNCT07826910Written as Atogepant 60 mg
- Comparing Migraine Preventive Therapies vs. Anti-CGRP Therapies for Tinnitus in Patients With Migraine (COMPACT-PM)Not yet recruitingPhase 4Stanford UniversityNCT07655440Written as Atogepant
- Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With MigraineEnrolling by invitationPhase 3AbbVieNCT05707949Written as Atogepant
- Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With MigraineCompletedPhase 3AbbVieNCT06241313Written as Atogepant
- Study of Oral Atogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual MigraineActive, not recruitingPhase 3AbbVieNCT06806293Written as Atogepant
- Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic MigraineCompletedPhase 3AbbVieNCT05216263Written as Atogepant
- Study of Oral Atogepant Tablets to Assess Change in Disease Activity in Adult Japanese Participants With Episodic MigraineCompletedPhase 3AbbVieNCT05861427Written as Atogepant
- A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic MigraineCompletedPhase 3AbbVieNCT04686136Written as Atogepant 60 mg
- A Study Evaluating Oral Atogepant for the Prevention of Migraine in Japanese Participants With Chronic or Episodic MigraineCompletedPhase 3AbbVieNCT04437433Written as Atogepant 60 mg
- Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With MigraineCompletedPhase 4AbbVieNCT05264129Written as Atogepant
- Study to Assess Adverse Events and Compare How Oral Ubrogepant and Oral Atogepant Moves Through the Body of Healthy Female Adult VolunteersCompletedPhase 1AbbVieNCT05892757Written as Atogepant
- Atogepant for Prophylaxis of Migraine in Participants Who Failed Previous Oral Prophylactic Treatments.CompletedPhase 3AllerganNCT04740827Written as Atogepant 60 mg
- Study to Assess Adverse Events (AEs) When Oral Atogepant Tablet is Given to Adult Chinese Participants Who Completed Study 3101-303-002 to Prevent Chronic MigraineCompletedPhase 3AllerganNCT04829747Written as Atogepant
- Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic MigraineCompletedPhase 3AllerganNCT03855137Written as Atogepant 30 mg
- Study To Assess Adverse Events and Drug to Drug Interaction of Oral Tablet Atogepant and Ubrogepant in Adult Participants With a History of MigraineCompletedPhase 1AbbVieNCT04818515Written as Atogepant
- Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic MigraineCompletedPhase 3AllerganNCT03939312Written as Atogepant
- 12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic MigraineCompletedPhase 3AllerganNCT03777059Written as Atogepant
See all 22 studies that test atogepant →
Given in every arm · 1 — atogepant is usual care beside what is tested
Codes
What other systems call atogepant · ClinicalTrials.gg INT001702
- MeSH (NLM) C000718987atogepantConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 7CRV8RR151ATOGEPANTConfirmed FDA, NLM, Wikidata
- RxNorm 2571813One source FDA
- Wikidata Q76797798atogepantConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C167018AtogepantOne source FDA
- DrugBank DB16098One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000718987 | atogepant | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 7CRV8RR151 | ATOGEPANT | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2571813 | — | One source FDA |
| Wikidata | Q76797798 | atogepant | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C167018 | Atogepant | One source FDA |
| DrugBank | DB16098 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.